latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/oncosil-implant-gets-us-fda-breakthrough-device-tag-for-pancreatic-cancer-57633540 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

OncoSil implant gets US FDA breakthrough device tag for pancreatic cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


OncoSil implant gets US FDA breakthrough device tag for pancreatic cancer

OncoSil Medical Ltd. said the U.S. Food and Drug Administration granted breakthrough device designation to OncoSil device for treating pancreatic cancer in combination with chemotherapy.

The tag will allow for expedited approval of the device, as it may provide more effective treatment of life-threatening or irreversibly debilitating diseases.

OncoSil device is implanted into the patient's pancreatic tumor to deliver a specific dose of the drug.

New South Wales, Australia-based OncoSil Medical develops localized treatments for pancreatic and liver cancer.